ShivaaniKummarMD

PubMed

• The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers.
  Allison Dunn, Naoko Takebe, Alice Chen, Shivaani Kummar, Richard Piekarz, Brian Kiesel, Nancy Moore, James Doroshow, Jan H Beumer, Jogarao V S Gobburu> ;Cancer Chemotherapy and Pharmacology. 2024 Mar 14
• Phase I Study of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors.
  Tolcher, A., Brody, J., Rajakumaraswamy, N., Kuhne, M., Trowe, T., Dauki, A., Kochikar Pai, S., Han, L., Lin, K., Petrarca, M., Kummar, S.> ;Clinical Cancer Research. 2024 Jan 31
• Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
  Arjun Mittra, Geraldine H O' Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Lawrence Rubinstein, Lamin Juwara, Deborah Wilsker, Jiuping Ji, Brandon Mi...> ;Cancer Chemotherapy and Pharmacology. 2024 Mar 1
• 2 citations
  Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
  Shivaani Kummar, Lin Shen, David S Hong, Ray McDermott, Vicki L Keedy, Michela Casanova, George D Demetri, Afshin Dowlati, Soledad Gallego Melcón, Ulrik N Lassen, Serg...> ;Cancer. 2023 Dec 1
• 3 citations
  Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network-Based Artificial Intelligence Tool.
  Savitri Krishnamurthy, Parag Jain, Debu Tripathy, Roland Basset, Ramandeep Randhawa, Hassan Muhammad, Wei Huang, Hua Yang, Shivaani Kummar, George Wilding, Rajat Roy> ;JCO Clinical Cancer Informatics. 2023 Mar 1
• 1 citations
  Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Eregressions.
  Jan H Beumer, Benjamin C Kennard, Julianne L Holleran, Nancy Moore, Jennifer Zlott, Brian M Miller, Shivaani Kummar, Alice Chen, James Doroshow, Wansu Park, Jogarao Go...> ;Cancer Chemotherapy and Pharmacology. 2023 Mar 1
• Combining Poly (ADP-Ribose) Polymerase (PARP) Inhibitors with Chemotherapeutic Agents: Promise and Challenges.
  Kyaw Zin Thein, Rajat Thawani, Shivaani Kummar> ;Cancer Treatment and Research. 2023 Jan 1
• Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?
  Rajat Thawani, Shivaani Kummar> ;JAMA Oncology. 2023 Jan 1
• 4 citations
  Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.
  James Nguyen, Naoko Takebe, Shivaani Kummar, Albiruni Razak, Sant P Chawla, Suzanne George, Shreyaskumar R Patel, Mary Louise Keohan, Sujana Movva, Geraldine O'Sulliva...> ;Clinical Cancer Research. 2023 Apr 3
• 2 citations
  Increasing patient participation in oncology clinical trials.
  Jie Chen, Ying Lu, Shivaani Kummar> ;Cancer Medicine. 2023 Feb 1
• 15 citations
  First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
  Timothy A Yap, Justin F Gainor, Margaret K Callahan, Gerald S Falchook, Russell K Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T Gibney, Howard A Burris, Sco...> ;Clinical Cancer Research. 2022 Sep 1
• 34 citations
  Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
  Steven G Waguespack, Alexander Drilon, Jessica J Lin, Marcia S Brose, Ray McDermott, Mohammed Almubarak, Jessica Bauman, Michela Casanova, Anuradha Krishnamurthy, Shiv...> ;European Journal of Endocrinology. 2022 Apr 29
• 5 citations
  A Novel Artificial Intelligence-Powered Method for Prediction of Early Recurrence of Prostate Cancer After Prostatectomy and Cancer Drivers.
  Wei Huang, Ramandeep Randhawa, Parag Jain, Samuel Hubbard, Jens Eickhoff, Shivaani Kummar, George Wilding, Hirak Basu, Rajat Roy> ;JCO Clinical Cancer Informatics. 2022 Feb 1
• 24 citations
  Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.
  Alexander Drilon, Daniel S W Tan, Ulrik N Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D Patel, Lee Rosen, Benjamin Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Breg...> ;JCO Precision Oncology. 2022 Jan 1
• 1 citations
  Diagnosis and management of TRK fusion cancer.
  Shivaani Kummar, Antoine Italiano, Marcia S Brose, Josh J Carlson, Sean D Sullivan, Ulrik Lassen, Noah Federman> ;The American Journal of Managed Care. 2022 Jan 1
• 5 citations
  Clinical activity of single-agent cabozantinib (XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft tissue sarcomas.
  Geraldine O'Sullivan Coyne, S. Kummar, James C. Hu, Kristen N. Ganjoo, Warren A. Chow, Khanh T. Do, Jennifer Zlott, Ashley Bruns, Larry Rubinstein, Jared C. Foster, La...> ;Clinical Cancer Research. 2021 Oct 29
• 31 citations
  Harnessing the predictive power of preclinical models for oncology drug development.
  Alexander Honkala, Sanjay V. Malhotra, S. Kummar, Melissa R. Junttila> ;Nature Reviews. Drug Discovery. 2021 Oct 26
• 11 citations
  Tissue-Agnostic Drug Development: A New Path to Drug Approval.
  Kyaw Zin Thein, Steven Lemery, S. Kummar> ;Cancer Discovery. 2021 Sep 1
• 3 citations
  Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
  S. Kummar, Apurva K. Srivastava, Tony Navas, Fabiola Cecchi, Young H. Lee, Donald P. Bottaro, Sook Ryun Park, Khanh T. Do, Woondong Jeong, Barry C. Johnson, Andrea Reg...> ;Investigational New Drugs. 2021 Jun 28
• 31 citations
  First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
  Michael L. Maitland, Jasgit C. Sachdev, Manish R. Sharma, Victor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal Lakhani, Allison R Moreau, Dawei...> ;Clinical Cancer Research. 2021 Aug 15
• 30 citations
  Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors.
  Naoko Takebe, Abdul Rafeh Naqash, Geraldine O'Sullivan Coyne, Shivaani Kummar, Khanh T. Do, Ashley Bruns, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, Richard Pieka...> ;Clinical Cancer Research. 2021 Apr 16
• 7 citations
  Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
  Shivaani Kummar, Jordan Berlin, Leo Mascarenhas, Cornelis M. van Tilburg, Birgit Geoerger, Ulrik Lassen, Russell J. Schilder, Brian Turpin, Shivani Nanda, Karen Keatin...> ;Current Problems in Cancer. 2021 Apr 2
• 6 citations
  Phase 1 study of Z-endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors.
  Naoko Takebe, Geraldine O'Sullivan Coyne, S. Kummar, Jerry M. Collins, Joel M. Reid, Richard Piekarz, Nancy Moore, Lamin Juwara, Barry C. Johnson, Rachel Bishop, Frank...> ;Oncotarget. 2021 Feb 16
• 21 citations
  Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
  Alice P. Chen, S. Kummar, Nancy Moore, Larry Rubinstein, Yingdong Zhao, P. Mickey Williams, Alida Palmisano, David J. Sims, Geraldine O'Sullivan Coyne, Christina L. Ro...> ;JCO Precision Oncology. 2021 Jan 12
• 16 citations
  Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis.
  Antoine Italiano, Shivani Nanda, Andrew Briggs, Jesús García-Foncillas, Ulrik Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, David S. Hong, Theodore ...> ;Cancers. 2020 Nov 4
• Join now to see all